DDInter1835 DDInter1752
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Drug-resistant bacteria, such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and penicillin-resistant _Streptococcus penumoniae_, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than [linezolid].[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Topotecan {u} (Compound) treats {v} (Disease) peripheral nervous system neoplasm
Topotecan {u} (Compound) binds {v} (Gene) TOP1
Topotecan {u} (Compound) upregulates {v} (Gene) ALDH5A1
Topotecan {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Topotecan {u} (Compound) downregulates {v} (Gene) CCNF
Topotecan {u} (Compound) causes {v} (Side Effect) Mucosal inflammation
Topotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gemifloxacin
Topotecan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Topotecan (Compound) treats peripheral nervous system neoplasm (Disease)
Topotecan (Compound) binds TOP1 (Gene)
Topotecan (Compound) upregulates ALDH5A1 (Gene)
Topotecan (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Topotecan (Compound) downregulates CCNF (Gene)
Topotecan (Compound) causes Mucosal inflammation (Side Effect)
Topotecan may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin
Topotecan may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel